Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression
- PMID: 1898655
- PMCID: PMC295046
- DOI: 10.1172/JCI114984
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression
Abstract
The melanoma cell line FO-1 does not express HLA class I antigens and does not acquire them on the cell surface after incubation with IFN-gamma. Immunochemical studies showed that FO-1 cells synthesize HLA class I heavy chain, but do not synthesize beta 2-microglobulin (beta 2-mu). The latter abnormality is associated with lack of beta 2-mu mRNA which remains undetectable in FO-1 cells incubated with IFN-gamma. The defect was identified as a genetic lesion in the B2m gene, since DNA hybridization analysis detected a deletion of the first exon of the 5'-flanking region, and of a segment of the first intron of the B2m gene. HLA class I antigen expression was reconstituted on melanoma cells FO-1 after transfection with the wild-type mouse B2m gene, thereby confirming the abnormality of the endogenous B2m gene. The defect identified in FO-1 cells is distinct from that underlying the lack of HLA class I antigen expression by lymphoblastoid cells Daudi, but is remarkably similar to that causing lack of H-2 class I antigen expression by mouse lymphoblastoid cells R1 (TL-). These results suggest that genetic recombination in the 5' region of the B2m gene is a recurrent mechanism in B2m gene defects. In addition to contributing to our understanding of molecular abnormalities in HLA class I antigen expression by melanoma cells, FO-1 cells represent a useful model for analyzing the role of HLA class I antigens in the biology of melanoma cells and in their interaction with cells of the immune system.
Similar articles
-
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.J Clin Invest. 1991 Jul;88(1):282-9. doi: 10.1172/JCI115289. J Clin Invest. 1991. PMID: 1905328 Free PMC article.
-
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.J Clin Invest. 1993 Feb;91(2):684-92. doi: 10.1172/JCI116249. J Clin Invest. 1993. PMID: 8432869 Free PMC article.
-
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells.Eur J Immunol. 1998 Sep;28(9):2817-26. doi: 10.1002/(SICI)1521-4141(199809)28:09<2817::AID-IMMU2817>3.0.CO;2-M. Eur J Immunol. 1998. PMID: 9754569
-
Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance.Melanoma Res. 1997 Aug;7 Suppl 2:S67-74. Melanoma Res. 1997. PMID: 9578419 Review.
-
Effects of alpha-interferon on serum beta-2-microglobulin.Leuk Lymphoma. 1996 Apr;21(3-4):233-8. doi: 10.3109/10428199209067605. Leuk Lymphoma. 1996. PMID: 8726404 Review.
Cited by
-
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas.Front Oncol. 2021 Mar 5;11:596290. doi: 10.3389/fonc.2021.596290. eCollection 2021. Front Oncol. 2021. PMID: 33747915 Free PMC article. Review.
-
Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus.J Clin Pathol. 2006 Sep;59(9):952-7. doi: 10.1136/jcp.2005.031575. Epub 2006 Feb 7. J Clin Pathol. 2006. PMID: 16467164 Free PMC article.
-
Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30. Nat Rev Immunol. 2020. PMID: 31570880 Free PMC article. Review.
-
Stromal cells from human decidua exert a strong inhibitory effect on NK cell function and dendritic cell differentiation.PLoS One. 2014 Feb 20;9(2):e89006. doi: 10.1371/journal.pone.0089006. eCollection 2014. PLoS One. 2014. PMID: 24586479 Free PMC article.
-
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303. Cancer J. 2018. PMID: 29360728 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous